Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients.
OBJECTIVE
This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients.


METHODS
One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study.


RESULTS
CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies.


CONCLUSIONS
Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.
Kinouchi
Kenichiro
K
Department of Endocrinology, Metabolism, and Nephrology, Keio University School of Medicine, Tokyo, Japan.
Ichihara
Atsuhiro
A
Sakoda
Mariyo
M
Kurauchi-Mito
Asako
A
Murohashi-Bokuda
Kanako
K
Itoh
Hiroshi
H
D000328:Adult; D000419:Albuminuria / Q000188:drug therapy / Q000503:physiopathology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000842:Ankle / Q000098:blood supply; D001158:Arteries / Q000187:drug effects / Q000503:physiopathology; D001562:Benzimidazoles / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination / Q000379:methods; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D008955:Models, Cardiovascular; D000077333:Telmisartan; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D002121:Calcium Channel Blockers; D000077333:Telmisartan